We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Sleep Disorder Linked with Abnormal Lipid Levels

By LabMedica International staff writers
Posted on 05 Sep 2018
Obstructive sleep apnea is a disorder in which breathing is repetitively interrupted during sleep due to collapse of the upper airway. More...
An apnea is defined as complete cessation of breathing lasting 10 seconds or greater.

Dyslipidemia is an abnormal amount of lipids such as triglycerides, cholesterol and/or fat phospholipids in the blood. Both obstructive sleep apnea (OSA) and dyslipidemia are independent risk factors for cardiovascular disease.

An international team of investigators led by scientists at the Sahlgrenska Academy (Gothenburg, Sweden) carried out a cross‐sectional analysis that included 8,592 patients without physician‐diagnosed hyperlipidemia or reported intake of a lipid‐lowering drug (age 50.1 ± 12.7 years, 69.1% male, BMI: 30.8 ± 6.6 kg/m2, mean apnea–hypopnea index (AHI): 25.7 ± 25.9 events/hour). The independent relationship between measures of OSA (AHI, oxygen desaturation index (ODI), mean and lowest oxygen saturation) and lipid profile (total cholesterol (TC), high‐density was calculated.

The team reported that there was a dose response relationship between TC and ODI (mean ± SE (mg/dL): 180.33 ± 2.46, 184.59 ± 2.42, 185.44 ± 2.42 and 185.73 ± 2.44; across ODI quartiles I–IV). Triglycerides (TG) and low-density lipoprotein cholesterol (LDL-C) concentrations were better predicted by AHI than by ODI. High-density lipoprotein-cholesterol (HDL‐C) was significantly reduced in the highest AHI quartile (mean ± SE (mg/dL): 48.8 ± 1.49 versus 46.50 ± 1.48; AHI quartile I versus IV). Morbid obesity was associated with lower TC and higher HDL‐C values. Lipid status was influenced by geographical location with the highest TC concentration recorded in Northern Europe.

The authors concluded that OSA severity was independently associated with cholesterol and TG concentrations. HDL‐C, LDL‐C, and fasting TG was determined by means of general linear model analysis. Dr. Ludger Grote, MD, PhD, a professor and senior author of the study, said, “Our data clearly suggest that sleep apnea may have a negative impact on lipid levels, which may in part explain the association between sleep apnea and increased risk for cardiovascular disease. Patients with sleep apnea therefore need careful management of all cardiovascular risk factors including hyperlipidemia.” The study was published on August 21, 2018, in the journal Respirology.

Related Links:
Sahlgrenska Academy


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Gastrointestinal Panel
Xpert® GI Panel
Gold Member
Aspiration System
VACUSAFE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Tumor DNA is extracted from a pathology sample, and normal DNA is extracted from the buffy coat. Both samples undergo WGS to generate the patient-specific mutational signature. At each follow-up, ctDNA extracted from plasma undergoes WGS and is analyzed using a patient-derived signature and an artificial intelligence (AI) pattern recognition algorithm. FFPE: formalin fixed, paraffin embedded. (Snuderl M, Smadbeck J, Wilkins R, et al. The Journal of Molecular Diagnostics, 2026. DOI: 10.1016/j.jmoldx.2026.07.003)

Liquid Biopsy Detects Lung Cancer Recurrence Signals Months Before Imaging

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and remains a major cause of cancer-related death. Early-stage tumors are often treated surgically, but recurrence can still occur... Read more

Immunology

view channel
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more

Pathology

view channel
Image: HETA Quality Control identifies slide quality issues before analysis, while HETA Tumor Detect annotates tumor regions and flags slides likely to contain tumor during scanning. (Photo courtesy of Aignostics)

AI Pathology Platform Targets Workflow Delays and Molecular Test Failures

Pathology laboratories often rely on visual review of tissue slides to assess quality, identify tumors, count mitoses, and estimate tumor content. These tasks can be time-consuming and vary between readers,... Read more

Technology

view channel
Image: Signals LabGistics uses AI to turn natural-language instructions and SOPs into coordinated scientific workflows, helping connect teams, systems, and processes. (Photo courtesy of Revvity)

New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows

Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams.... Read more

Industry

view channel
Image: The acquisition of Reveal Genomics would expand Hologic’s oncology diagnostics portfolio to support treatment decisions for more women with breast cancer.

Hologic to Broaden Breast Cancer Testing Portfolio Through Reveal Genomics Acquisition

Hologic (Marlborough, MA, USA) has signed a definitive agreement to acquire Reveal Genomics (Barcelona, Spain), a precision oncology company developing genomic diagnostic tests to help personalize cancer treatment.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.